Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety and Tolerability of Two Fixed-Dose Combinations of Aclidinium Bromide With Two Doses of Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo All Administered Twice Daily in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease Patients.

NCT01078623 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01078623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01078623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety and Tolerability of Two Fixed-Dose Combinations of Aclidinium Bromide With Two Doses of Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo All Administered Twice Daily in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease Patients.
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2010
Completion date
September 30, 2010
Enrollment
176 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease